X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will work on an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients and BX211 for the treatment of diabetic foot osteomyelitis.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BiomX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 18, 2024
Details:
The combined company will work on an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients and BX211 for the treatment of diabetic foot osteomyelitis.
Lead Product(s): BX004
Therapeutic Area: Genetic Disease Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BiomX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 06, 2024
Details:
The financing will be used in continuing clinical progression of APT’s pipeline of bacteriophage-based therapies that specifically target and kill bacteria, to create personalized treatments for patients with difficult-to-treat AMR infections.
Lead Product(s): Bacteriophage-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deerfield Management
Deal Size: $24.0 million Upfront Cash: $12.0 million
Deal Type: Series B Financing June 13, 2023
Details:
Under the agreement, Hadasit and Yissum grants APT exclusive rights to make, use, and sell licensed phages for human bacteriophage-based therapy, with the right to sublicense through multiple tiers.
Lead Product(s): Bacteriophage-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Israeli Phage Therapy Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 24, 2023
Details:
The investigational phage therapeutic, WRAIR-PAM-CF1, was developed by the Walter Reed Army Institute of Research (WRAIR) and is licensed to and manufactured by APT. The trial is expected to enroll a total of 72 patients at multiple sites across the country.
Lead Product(s): WRAIR_EPa11,WRAIR_EPa39,WRAIR_EPa83
Therapeutic Area: Genetic Disease Product Name: WRAIR_PAM-CF1
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
Phages from the APT phage bank (Phage-based Therapy) are precision-matched to the patient’s infections through a proprietary phage susceptibility test (PST) that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.
Lead Product(s): Phage-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: PhageBank
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Proceeds of the AMR Action Fund’s investment are primarily intended to support APT’s clinical trials to address substantial unmet patient needs in Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO).
Lead Product(s): Phage Therapy,Antibiotic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deerfield Management
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 04, 2022
Details:
Funding will support the PhageBank™ platform to treat drug-resistant infections across multiple indications which leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage.
Lead Product(s): Bacteriophage Therapies
Therapeutic Area: Infections and Infectious Diseases Product Name: PhageBank
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $31.2 million Upfront Cash: Undisclosed
Deal Type: Funding September 30, 2021
Details:
In-vitro activity of multiple phage strain candidates were assessed by means of APT’s PhageBank™ Susceptibility Test (PST) to determine the clinically relevant selection.
Lead Product(s): Phage-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: PhageBank
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
APT’s PhageBank™ technology is a growing collection of hundreds of bacteriophage, collectively providing broad spectrum coverage against six of the highest priority multi-drug resistant bacterial pathogens.
Lead Product(s): Phage Therapy,Antibiotics
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deerfield Management
Deal Size: $40.8 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
